Related Experiment Video
Updated: Sep 17, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Trends in initial pharmacological treatment of asthma in primary care (2010-2021): A population-based study using the
Joana Antão1, Guilherme Rodrigues1, Qichen Deng2
1Lab3R - Respiratory Research and Rehabilitation Laboratory, School of Health Sciences (ESSUA) and Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal; Department of Medical Sciences, University of Aveiro, Aveiro, Portugal; Department of Research and Development, Ciro, Horn, the Netherlands; Department of Respiratory Medicine, Maastricht University Medical Centre, NUTRIM Institute for Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.
Introduction:
Real-world evidence of asthma management in primary care is limited but of paramount importance for improving care quality. This study described the trends of initial pharmacological treatments prescribed by Dutch general practitioners (GPs) from 2010 to 2021.
Methods:
This was a repeated cross-sectional study of adults with asthma using the PHARMO data network. Initial treatments were defined based on the first prescription within 90 days of diagnosis. Trends were analysed using joinpoint regression and compared across age groups and between sexes.
Results:
95,523 adults with asthma were included (39.9% male; median [Q1, Q3] age 45 [31, 59] years). SABA without ICS increased until 2018 from 17.0% to 29.5% and then decreased to 26.1% by 2021. In contrast, ICS-LABA decreased from 25.1% to 22.1% until 2018, increasing subsequently to 30.6% in 2021. ICS without LABA remained unchanged until 2013. Between 2013 and 2019, it increased from 13.8% to 15.8%, followed by a decline to 11.2%. Triple therapy was consistently around 1%. Patients without prescriptions for asthma decreased over the study period (34.2%-25%). SABA without ICS was more prescribed to young adults than middle-aged adults and the elderly, whereas the opposite was found for ICS-LABA and ICS-LABA-LAMA in both sexes (all adjusted-p<0.05).
Conclusion:
The observed changes in initial treatment of asthma in Dutch primary care seem to reflect the updating of recommendations, however, many patients were on SABA without ICS or did not receive a prescription from their GP, emphasising the need for strategies to improve asthma care. Age-related differences warrant further investigation.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...